Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Chlorpromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 3/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 9/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 9/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | TP53 | P04637 | 6/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 5/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 5/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorpromazine SCHEMBL29358018 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL29367385 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL41771 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL8503036 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL27940552 | 0.99 | CYP1A2 (0.97) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL23326209 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL29351728 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL5483904 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL29714121 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL27869706 | 0.99 | CYP1A2 (0.97) | CYP1A2CYP2D6HTR1ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 49346 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-122072257-A | Method for rapidly detecting poison in blood | 中国科学院大连化学物理研究所 | 2026-05-22 | — | — | CN | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026106908-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | NEUHYLL THERAPEUTICS INC. (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| CN-122028919-A | Compositions and methods for treating cancer by affecting cancer cell membrane receptors and exosomes derived therefrom | 黄奇英 | 2026-05-12 | — | — | CN | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| EP-3411059-B1 | METHOD TO ENHANCE THE EFFICIENCY OF SYSTEMIC AAV GENE DELIVERY TO THE CENTRAL NERVOUS SYSTEM | UNIV MASSACHUSETTS (US) | 2026-05-06 | — | — | EP | claimed |
| US-4197288-A | Neuroleptic radioreceptor assay method and kit | BURROUGHS WELLCOME CO. (US) | 1980-04-08 | — | — | US | claimed |
| US-4175119-A | Composition and method to prevent accidental and intentional overdosage with psychoactive drugs | PORTER GARRY L | 1979-11-20 | — | — | US | claimed |
| US-4153713-A | NEUROPSYCHOTROPIC AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1979-05-08 | — | — | US | claimed |
| US-4138484-A | CHLORPROMAZINE OR THORIDAZINE WITH G-HYDROXYBUTYROLACTONE | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1979-02-06 | — | — | US | claimed |
| US-4129652-A | CHLORPROMAZINE OR THIORIDAZINE AND 5-ETHYL-5-PHENYL-2-PYRROLIDONE OR 1-HYDROXY-3-AMINO-2-PYRROLIDONE OR SALTS | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1978-12-12 | — | — | US | claimed |
| US-4036227-A | Osmotic releasing device having a plurality of release rate patterns | ALZA CORPORATION (US) | 1977-07-19 | — | — | US | claimed |
| US-4012495-A | USED IN TREATING NEUROLOGICAL AND PSYCHIC DISORDERS | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-03-15 | — | — | US | claimed |
| US-3993072-A | Microporous drug delivery device | ALZA CORPORATION (US) | 1976-11-23 | — | — | US | claimed |
| US-3978216-A | AMINOOXYACETIC ACID | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1976-08-31 | — | — | US | claimed |
| US-3976763-A | Chlorpromazine assay | HOFFMANN-LA ROCHE INC. (US) | 1976-08-24 | — | — | US | claimed |